Intrapericardial minocycline sclerosis for malignant pericardial effusion

Ilan Lashevsky, Rami Ben Yosef, Diana Rinkevich, Shimon Reisner, Walter Markiewicz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Study objective: To evaluate the effectiveness and safety of minocycline hydrochloride (minocycline) intrapericardially in patients with malignant pericardial effusion. Design: Consecutive patients admitted to the hospital during a 32-month period received intrapericardial minocycline. Setting: A 900-bed university hospital. Patients: Fourteen consecutive patients with malignant pcricardial effusion. Intervention: Following percutaneous insertion of a pericardial drain, minocycline was administered at a dosage of 10 mg/kg every 48 h until fluid drainage stopped or until further therapy was deemed necessary. Measurements: Complications associated with therapy, total minocycline requirements, immediate and late failure of therapy, and clinical and echocardiographic follow-up of at least 6 months. Results: Mean amount of minocycline administered was 1.9±1.0 g given in 2.4 divided doses. Total drainage time was 5.4±2.5 days. Recurrence of malignant pericardial effusion was seen in only 1 of 14 patients. Death occurred in 10 patients due to severe metastatic disease in all. Minocycline instillation was associated with severe chest pain in seven patients, and with ECG changes suggesting pericardial or subepicardial injury in two patients. Conclusion: (1) Intrapericardial minocycline instillation is very effective in preventing rccurrence of malignant pericardial effusion. (2) Minocycline is irritative to the pericardium and may cause severe chest pain with transient ECG changes, suggesting pericardial or subepicardial injury.

Original languageEnglish (US)
Pages (from-to)1452-1454
Number of pages3
JournalChest
Volume109
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Minocycline
Pericardial Effusion
Sclerosis
Chest Pain
Drainage
Electrocardiography
Pericardium
Wounds and Injuries
Therapeutics
Safety
Recurrence

Keywords

  • cardiac tamponade
  • minocycline
  • pericardial effusion
  • tetracycline

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lashevsky, I., Yosef, R. B., Rinkevich, D., Reisner, S., & Markiewicz, W. (1996). Intrapericardial minocycline sclerosis for malignant pericardial effusion. Chest, 109(6), 1452-1454.

Intrapericardial minocycline sclerosis for malignant pericardial effusion. / Lashevsky, Ilan; Yosef, Rami Ben; Rinkevich, Diana; Reisner, Shimon; Markiewicz, Walter.

In: Chest, Vol. 109, No. 6, 1996, p. 1452-1454.

Research output: Contribution to journalArticle

Lashevsky, I, Yosef, RB, Rinkevich, D, Reisner, S & Markiewicz, W 1996, 'Intrapericardial minocycline sclerosis for malignant pericardial effusion', Chest, vol. 109, no. 6, pp. 1452-1454.
Lashevsky I, Yosef RB, Rinkevich D, Reisner S, Markiewicz W. Intrapericardial minocycline sclerosis for malignant pericardial effusion. Chest. 1996;109(6):1452-1454.
Lashevsky, Ilan ; Yosef, Rami Ben ; Rinkevich, Diana ; Reisner, Shimon ; Markiewicz, Walter. / Intrapericardial minocycline sclerosis for malignant pericardial effusion. In: Chest. 1996 ; Vol. 109, No. 6. pp. 1452-1454.
@article{a16a1282af814a65903a6752e9c3e3ef,
title = "Intrapericardial minocycline sclerosis for malignant pericardial effusion",
abstract = "Study objective: To evaluate the effectiveness and safety of minocycline hydrochloride (minocycline) intrapericardially in patients with malignant pericardial effusion. Design: Consecutive patients admitted to the hospital during a 32-month period received intrapericardial minocycline. Setting: A 900-bed university hospital. Patients: Fourteen consecutive patients with malignant pcricardial effusion. Intervention: Following percutaneous insertion of a pericardial drain, minocycline was administered at a dosage of 10 mg/kg every 48 h until fluid drainage stopped or until further therapy was deemed necessary. Measurements: Complications associated with therapy, total minocycline requirements, immediate and late failure of therapy, and clinical and echocardiographic follow-up of at least 6 months. Results: Mean amount of minocycline administered was 1.9±1.0 g given in 2.4 divided doses. Total drainage time was 5.4±2.5 days. Recurrence of malignant pericardial effusion was seen in only 1 of 14 patients. Death occurred in 10 patients due to severe metastatic disease in all. Minocycline instillation was associated with severe chest pain in seven patients, and with ECG changes suggesting pericardial or subepicardial injury in two patients. Conclusion: (1) Intrapericardial minocycline instillation is very effective in preventing rccurrence of malignant pericardial effusion. (2) Minocycline is irritative to the pericardium and may cause severe chest pain with transient ECG changes, suggesting pericardial or subepicardial injury.",
keywords = "cardiac tamponade, minocycline, pericardial effusion, tetracycline",
author = "Ilan Lashevsky and Yosef, {Rami Ben} and Diana Rinkevich and Shimon Reisner and Walter Markiewicz",
year = "1996",
language = "English (US)",
volume = "109",
pages = "1452--1454",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Intrapericardial minocycline sclerosis for malignant pericardial effusion

AU - Lashevsky, Ilan

AU - Yosef, Rami Ben

AU - Rinkevich, Diana

AU - Reisner, Shimon

AU - Markiewicz, Walter

PY - 1996

Y1 - 1996

N2 - Study objective: To evaluate the effectiveness and safety of minocycline hydrochloride (minocycline) intrapericardially in patients with malignant pericardial effusion. Design: Consecutive patients admitted to the hospital during a 32-month period received intrapericardial minocycline. Setting: A 900-bed university hospital. Patients: Fourteen consecutive patients with malignant pcricardial effusion. Intervention: Following percutaneous insertion of a pericardial drain, minocycline was administered at a dosage of 10 mg/kg every 48 h until fluid drainage stopped or until further therapy was deemed necessary. Measurements: Complications associated with therapy, total minocycline requirements, immediate and late failure of therapy, and clinical and echocardiographic follow-up of at least 6 months. Results: Mean amount of minocycline administered was 1.9±1.0 g given in 2.4 divided doses. Total drainage time was 5.4±2.5 days. Recurrence of malignant pericardial effusion was seen in only 1 of 14 patients. Death occurred in 10 patients due to severe metastatic disease in all. Minocycline instillation was associated with severe chest pain in seven patients, and with ECG changes suggesting pericardial or subepicardial injury in two patients. Conclusion: (1) Intrapericardial minocycline instillation is very effective in preventing rccurrence of malignant pericardial effusion. (2) Minocycline is irritative to the pericardium and may cause severe chest pain with transient ECG changes, suggesting pericardial or subepicardial injury.

AB - Study objective: To evaluate the effectiveness and safety of minocycline hydrochloride (minocycline) intrapericardially in patients with malignant pericardial effusion. Design: Consecutive patients admitted to the hospital during a 32-month period received intrapericardial minocycline. Setting: A 900-bed university hospital. Patients: Fourteen consecutive patients with malignant pcricardial effusion. Intervention: Following percutaneous insertion of a pericardial drain, minocycline was administered at a dosage of 10 mg/kg every 48 h until fluid drainage stopped or until further therapy was deemed necessary. Measurements: Complications associated with therapy, total minocycline requirements, immediate and late failure of therapy, and clinical and echocardiographic follow-up of at least 6 months. Results: Mean amount of minocycline administered was 1.9±1.0 g given in 2.4 divided doses. Total drainage time was 5.4±2.5 days. Recurrence of malignant pericardial effusion was seen in only 1 of 14 patients. Death occurred in 10 patients due to severe metastatic disease in all. Minocycline instillation was associated with severe chest pain in seven patients, and with ECG changes suggesting pericardial or subepicardial injury in two patients. Conclusion: (1) Intrapericardial minocycline instillation is very effective in preventing rccurrence of malignant pericardial effusion. (2) Minocycline is irritative to the pericardium and may cause severe chest pain with transient ECG changes, suggesting pericardial or subepicardial injury.

KW - cardiac tamponade

KW - minocycline

KW - pericardial effusion

KW - tetracycline

UR - http://www.scopus.com/inward/record.url?scp=0030015234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030015234&partnerID=8YFLogxK

M3 - Article

C2 - 8769492

AN - SCOPUS:0030015234

VL - 109

SP - 1452

EP - 1454

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -